All Outputs (4)

Specialist treatment for persistent depression in secondary care: Sustained effects from a multicentre UK study at 24 and 36 months (2023)
Journal Article
Nixon, N., Guo, B., Kaylor-Hughes, C., Simpson, S., Garland, A., Dalgleish, T., & Morriss, R. (2024). Specialist treatment for persistent depression in secondary care: Sustained effects from a multicentre UK study at 24 and 36 months. Journal of Affective Disorders, 345, 70-77. https://doi.org/10.1016/j.jad.2023.10.105

Background: Despite the known health costs of persistent depression, there is no established service framework for the treatment of this disorder and a lack of long-term outcome data to inform commissioning. To address this gap, we report the long-te... Read More about Specialist treatment for persistent depression in secondary care: Sustained effects from a multicentre UK study at 24 and 36 months.

Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial (2023)
Journal Article
Morriss, R., Patel, S., Boutry, C., Patel, P., Guo, B., Briley, P. M., …Kai, J. (2023). Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial. Lancet Psychiatry, 10(3), 172-183. https://doi.org/10.1016/S2215-0366%2823%2900007-X

Background: Randomised sham-controlled trials of cranial electrostimulation with the Alpha-Stim Anxiety Insomnia and Depression (AID) device have reported improved anxiety and depression symptoms; however, no adequately powered sham-controlled trials... Read More about Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial.

A randomised controlled trial investigating the clinical and cost-effectiveness of Alpha-Stim AID cranial electrotherapy stimulation (CES) in patients seeking treatment for moderate severity depression in primary care (Alpha-Stim-D Trial) (2022)
Journal Article
Patel, S., Boutry, C., Patel, P., Craven, M. P., Guo, B., Zafar, A., …Morriss, R. (2022). A randomised controlled trial investigating the clinical and cost-effectiveness of Alpha-Stim AID cranial electrotherapy stimulation (CES) in patients seeking treatment for moderate severity depression in primary care (Alpha-Stim-D Trial). Trials, 23(1), Article 250. https://doi.org/10.1186/s13063-022-06192-1

Background: Major depression is the second leading cause of years lost to disability worldwide and is a leading contributor to suicide. However, first-line antidepressants are only fully effective for 33%, and only 40% of those offered psychological... Read More about A randomised controlled trial investigating the clinical and cost-effectiveness of Alpha-Stim AID cranial electrotherapy stimulation (CES) in patients seeking treatment for moderate severity depression in primary care (Alpha-Stim-D Trial).

Biological vulnerability to depression: Linked structural and functional brain network findings (2014)
Journal Article
Worwood, G., Nixon, E., Palaniyappan, L., Nixon, N. L., Liddle, P. F., Nixon, N. L., …Palaniyappan, L. (2014). Biological vulnerability to depression: Linked structural and functional brain network findings. British Journal of Psychiatry, 204(4), 283-289. https://doi.org/10.1192/bjp.bp.113.129965

Background: Patients in recovery following episodes of major depressive disorder (MDD) remain highly vulnerable to future recurrence. Although psychological determinants of this risk are well established, little is known about associated biological m... Read More about Biological vulnerability to depression: Linked structural and functional brain network findings.